TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity
Details
Publication Year 2023-01-15,Volume 129,Issue #2,Page 175-180
Journal Title
Cancer
Publication Type
Review
Abstract
TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
Publisher
Wiley
Keywords
Humans; *Myelodysplastic Syndromes/drug therapy; *Leukemia, Myeloid, Acute/genetics/drug therapy; Leukocytes; Tumor Suppressor Protein p53/genetics; Tp53; acute myeloid leukemia (AML); cutoff; excess blasts; myelodysplastic syndrome (MDS); p53
Department(s)
Clinical Haematology
PubMed ID
36397669
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-06-13 07:55:28
Last Modified: 2023-06-13 07:56:08

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙